GleamWall
中文EN

PCSA Processa Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.81M$649,877$1.81M$2.11M$1.66M$2.45M$1.59M$1.71M
SG&A expense$4.29M$1.69M$1.52M$1.59M$1.83M$1.50M$1.26M$1.02M
Operating income-$184.13M-$2.34M-$3.33M-$3.70M-$3.49M-$3.95M-$2.85M-$2.73M
Pretax income——-$3.38M———-$2.83M—
Net income-$183.16M-$3.27M-$3.38M-$3.36M-$3.44M-$3.93M-$2.83M-$2.73M
EBITDA-$184.13M-$2.34M-$3.33M-$3.70M-$3.49M-$3.95M-$2.85M-$2.73M
EPS (basic)-61.58-1.19-1.29—-1.81-6.26-7.58—
EPS (diluted)-61.58-1.19-1.29—-1.81-6.26-7.58—
Weighted avg. shares (diluted)2.97M2.75M2.62M—1.90M628,796373,967—
Balance sheet
Cash & equivalents$180.21M$196,325$1.69M$5.54M$6.31M$6.94M$2.90M$1.19M
Current assets$182.01M$2.07M$1.94M$5.67M$6.59M$7.15M$3.76M$1.88M
PP&E, net$3,000$3,210$3,511$4,000$4,113——$5,016
Total assets$182.01M$2.07M$4.52M$7.81M$7.58M$8.18M$4.81M$3.23M
Current liabilities$1.86M$2.39M$1.98M$2.24M$1.75M$2.07M$1.28M$1.53M
Total liabilities$1.86M$2.39M$1.98M$2.24M$1.75M$2.07M$1.28M$1.53M
Shareholders' equity-$181.38M-$318,000$2.54M$5.58M$5.83M$6.11M$3.53M$1.70M
Shares outstanding2.80M2.79M2.68M2.57M52.86M40.28M5.27M148,108
Cash flow statement
Operating cash flow-$5.18M-$2.00M-$3.59M-$2.90M-$3.48M-$2.27M-$2.73M-$2.25M
Capital expenditure———————$0
Free cash flow———————-$2.25M
Investing cash flow-$1.90M$186,000-$500,000————$0
Financing cash flow$187.13M$315,167$244,783$2.98M$2.86M$6.31M$4.44M$547,582
Depreciation & amortization$398$301$301$301$301$301$301$301
Stock-based compensation$846,000$92,105$95,963$123,541$303,000$203,251$227,711$155,048

Free plan shows the latest 8 periods; Pro shows all 58 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.